Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTLNASDAQ:KMDANASDAQ:MGNXNASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.53+4.1%$1.43$1.11▼$5.00$407.20M1.771.49 million shs970,141 shsKMDAKamada$6.74-1.3%$6.57$4.74▼$9.16$387.42M0.9490,072 shs54,191 shsMGNXMacroGenics$1.58+6.0%$1.50$0.99▼$5.77$99.68M2.2808,123 shs301,924 shsPRTAProthena$6.55-4.0%$9.80$6.47▼$25.42$352.57M0.11594,725 shs933,156 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+4.08%+18.60%-4.38%-21.54%-60.16%KMDAKamada-1.32%-1.75%+4.17%-9.65%+26.69%MGNXMacroGenics+6.04%+2.60%+3.95%-42.75%-66.38%PRTAProthena-3.96%-2.53%-31.34%-57.90%-69.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics3.0891 of 5 stars3.54.00.00.02.13.30.6KMDAKamada3.9195 of 5 stars3.43.00.00.02.61.73.8MGNXMacroGenics3.6835 of 5 stars3.21.00.04.42.32.50.6PRTAProthena3.853 of 5 stars4.43.00.00.04.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32509.15% UpsideKMDAKamada 2.75Moderate Buy$14.67117.61% UpsideMGNXMacroGenics 2.40Hold$6.13287.66% UpsidePRTAProthena 2.88Moderate Buy$51.71689.53% UpsideCurrent Analyst Ratings BreakdownLatest MGNX, PRTA, AUTL, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025MGNXMacroGenicsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.005/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/14/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $3.005/14/2025MGNXMacroGenicsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$6.00 ➝ $5.005/13/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$48.00 ➝ $30.005/9/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$80.00 ➝ $78.005/9/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$9.01M45.19N/AN/A$0.64 per share2.39KMDAKamada$167.24M2.32$0.38 per share17.90$4.25 per share1.59MGNXMacroGenics$152.43M0.65N/AN/A$2.46 per share0.64PRTAProthena$137.94M2.56N/AN/A$10.46 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$0.88N/AN/AN/AN/A-63.65%-36.54%N/AKMDAKamada$8.28M$0.2924.0721.060.979.92%6.30%4.49%N/AMGNXMacroGenics-$9.06M-$0.89N/AN/AN/A-69.07%-89.42%-38.57%8/5/2025 (Estimated)PRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%N/ALatest MGNX, PRTA, AUTL, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 million5/13/2025Q1 2025MGNXMacroGenics-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 million5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million3/20/2025Q4 2024MGNXMacroGenics-$0.23-$0.25-$0.02-$0.25$34.17 million$49.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ALatest MGNX, PRTA, AUTL, and KMDA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/5/2025KMDAKamada--$0.203/17/20253/17/20254/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A13.6913.69KMDAKamadaN/A4.842.73MGNXMacroGenicsN/A3.753.69PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%KMDAKamada20.38%MGNXMacroGenics96.89%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%KMDAKamada36.10%MGNXMacroGenics13.00%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.71 millionOptionableKMDAKamada36057.48 million36.73 millionOptionableMGNXMacroGenics43063.09 million55.67 millionOptionablePRTAProthena13053.83 million38.64 millionOptionableMGNX, PRTA, AUTL, and KMDA HeadlinesRecent News About These CompaniesBNP Paribas Financial Markets Purchases 41,541 Shares of Prothena Co. plc (NASDAQ:PRTA)May 22 at 3:19 AM | marketbeat.comBalyasny Asset Management L.P. Makes New $527,000 Investment in Prothena Co. plc (NASDAQ:PRTA)May 18, 2025 | marketbeat.comCantor Fitzgerald Upgrades Prothena (NASDAQ:PRTA) to "Strong-Buy"May 17, 2025 | marketbeat.comProsight Management LP Sells 65,345 Shares of Prothena Co. plc (NASDAQ:PRTA)May 17, 2025 | marketbeat.comProthena Shareholders Approve Key Amendments at AGMMay 16, 2025 | tipranks.comCantor Fitzgerald Expects Increased Earnings for ProthenaMay 16, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Issues Quarterly Earnings ResultsMay 12, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Receives "Buy" Rating from Chardan CapitalMay 11, 2025 | marketbeat.comProthena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025May 9, 2025 | zacks.comProthena Corporation plc: Prothena Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deProthena Corp (PRTA) Sees Price Target Reduction by HC Wainwright & Co. | PRTA Stock NewsMay 9, 2025 | gurufocus.comProthena Corp (PRTA) Sees Price Target Adjusted by JMP Securities | PRTA Stock NewsMay 9, 2025 | gurufocus.comIs Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | msn.comProthena Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finance.yahoo.com3PRTA : Beyond The Numbers: 7 Analysts Discuss Prothena Corp StockMay 9, 2025 | benzinga.comTop 3 Health Care Stocks That Are Preparing To Pump This QuarterMay 9, 2025 | benzinga.comProthena (PRTA) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comProthena Co. plc (NASDAQ:PRTA) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 8, 2025 | marketbeat.comProthena Q1 2025 Earnings PreviewMay 7, 2025 | msn.comA Look Ahead: Prothena Corp's Earnings ForecastMay 7, 2025 | benzinga.comInsiders Re-Evaluate Their US$2.75m Stock Purchase As Prothena Falls To US$458mMay 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGNX, PRTA, AUTL, and KMDA Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.53 +0.06 (+4.08%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 05/22/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Kamada NASDAQ:KMDA$6.74 -0.09 (-1.32%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$6.76 +0.01 (+0.22%) As of 05/22/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.MacroGenics NASDAQ:MGNX$1.58 +0.09 (+6.04%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.32%) As of 05/22/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Prothena NASDAQ:PRTA$6.55 -0.27 (-3.96%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$6.90 +0.35 (+5.27%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Cathie Wood Just Bought a New Stake in Taiwan Semiconductor Stock Super Micro Computer Stock Clears New Path Higher on Saudi Orders Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Why Carnival Could Be the Ultimate Non-Tech Growth Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
